LEXX

MKT CAP:$20M

Lexaria Bioscience Corp.

Market Cap

$20M

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Healthcare·Biotechnology·🇨🇦·NASDAQ

Stock Price

$0.94+$0.29 (+44.31%)

Apr 24, 2026

Company Details

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's D...

CEO

Richard C. Christopher

IPO Date

Jan 12, 2021

Website

www.lexariabioscience.com

Key Metrics TTM

Revenue

$368.0K

-30.0% YoY

Net Income

-$10M

EPS (Diluted)

-$0.48

Free Cash Flow

-$9M

Revenue / Share

$0.02

Gross Margin

76.2%

Operating Margin

-2513.8%

Net Margin

-2589.7%

FCF Margin

-2562.6%

P/S

53.2x

P/E

—

Earnings Reports

Q2 2026

Apr 13, 2026

NEW

$20.0K-88.5%EPS -$0.06

Q1 2026

Jan 13, 2026

$0-100.0%EPS -$0.07

FY 2025

Nov 26, 2025

$705.9K+52.0%EPS -$0.66

Q4 2025

Nov 26, 2025

$174.0K+107.1%EPS -$0.14

Q3 2025

Jul 14, 2025

$174.0K+107.1%EPS -$0.21

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 22	$99.7K	$49.4K	-$2M
Q4 22	$111.2K	$34.3K	-$2M
Q1 23	$97.7K	$47.1K	-$2M
Q2 23	$20.0K	-$7.7K	-$1M
Q3 23	$77.7K	$40.0K	-$2M
Q4 23	$30.7K	-$25.4K	-$1M
Q1 24	$151.3K	$106.8K	-$1M
Q2 24	$145.0K	$129.1K	-$668.0K
Q3 24	$84.0K	$68.9K	-$2M
Q4 24	$84.0K	$67.6K	-$2M
Q1 25	$183.9K	$148.0K	-$3M
Q2 25	$174.0K	$156.2K	-$3M
Q3 25	$174.0K	$158.6K	-$4M
Q4 25	$174.0K	$152.6K	-$2M
Q1 26	$0	-$24.2K	-$2M
Q2 26	$20.0K	-$6.6K	-$1M

Valuation

Quarter	P/S	P/E
Q3 22	72.5x	—
Q4 22	69.4x	—
Q1 23	42.8x	—
Q2 23	54.9x	—
Q3 23	16.4x	—
Q4 23	30.1x	—
Q1 24	52.7x	—
Q2 24	60.1x	—
Q3 24	124.2x	—
Q4 24	81.9x	—
Q1 25	78.9x	—
Q2 25	44.5x	—
Q3 25	31.0x	—
Q4 25	29.1x	—
Q1 26	43.4x	—
Q2 26	41.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 22	-$1M	-$1M
Q4 22	-$1M	-$1M
Q1 23	-$1M	-$1M
Q2 23	-$1M	-$1M
Q3 23	-$2M	-$2M
Q4 23	-$2M	-$2M
Q1 24	-$1M	-$1M
Q2 24	-$619.6K	-$676.6K
Q3 24	-$1M	-$1M
Q4 24	-$2M	-$2M
Q1 25	-$3M	-$3M
Q2 25	-$1M	-$1M
Q3 25	-$4M	-$4M
Q4 25	-$3M	-$3M
Q1 26	-$984.1K	-$984.1K
Q2 26	-$2M	-$2M

Capital Expenditures

Quarter	CapEx
Q3 22	$38.0K
Q4 22	$50.0K
Q1 23	$34.8K
Q2 23	$32.7K
Q3 23	$33.6K
Q4 23	$68.4K
Q1 24	$40.0K
Q2 24	$57.0K
Q3 24	$22.0K
Q4 24	$69.6K
Q1 25	$37.8K
Q2 25	$0
Q3 25	$3
Q4 25	$0
Q1 26	$0
Q2 26	$55.9K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 22	-51.1%	-26.8%
Q4 22	+258.3%	+14.9%
Q1 23	+604.1%	+6.9%
Q2 23	-34.7%	-9.2%
Q3 23	-22.1%	+25.5%
Q4 23	-72.3%	-29.5%
Q1 24	+54.8%	-28.0%
Q2 24	+624.1%	-39.5%
Q3 24	+8.1%	-27.7%
Q4 24	+173.3%	+99.8%
Q1 25	+21.6%	+117.2%
Q2 25	+20.0%	+259.8%
Q3 25	+107.1%	+118.9%
Q4 25	+107.1%	+15.8%
Q1 26	-100.0%	-43.9%
Q2 26	-88.5%	-49.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 22	$111.2K	111.5%
Q4 22	$232.9K	209.5%
Q1 23	$68.8K	70.4%
Q2 23	$10.5K	52.6%
Q3 23	$81.4K	104.8%
Q4 23	$9.6K	31.3%
Q1 24	$54.0K	35.7%
Q2 24	$0	0.0%
Q3 24	$341.8K	406.9%
Q4 24	$96.5K	114.9%
Q1 25	$99.4K	54.1%
Q2 25	$167.2K	96.1%
Q3 25	$470.1K	270.2%
Q4 25	$122.7K	70.5%
Q1 26	$74.9K	—
Q2 26	$74.9K	374.5%

OpEx Breakdown

Quarter	R&D	SG&A
Q3 22	$752.1K	$1M
Q4 22	$356.2K	$1M
Q1 23	$829.5K	$913.0K
Q2 23	$696.2K	$619.8K
Q3 23	$2M	$800.2K
Q4 23	$500.4K	$588.3K
Q1 24	$574.5K	$671.4K
Q2 24	$245.8K	$551.3K
Q3 24	$573.1K	$1M
Q4 24	$967.2K	$1M
Q1 25	$2M	$813.9K
Q2 25	$2M	$1M
Q3 25	$3M	$1M
Q4 25	$2M	$745.3K
Q1 26	$671.3K	$878.1K
Q2 26	$475.4K	$969.9K

Revenue Segments

Quarter	IP Licensing
Q2 26	$20.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 22	$7M	$288.0K	$7M
Q4 22	$6M	$347.3K	$6M
Q1 23	$5M	$269.7K	$5M
Q2 23	$3M	$267.7K	$4M
Q3 23	$3M	$269.6K	$3M
Q4 23	$1M	$125.6K	$1M
Q1 24	$2M	$72.4K	$2M
Q2 24	$5M	$87.7K	$5M
Q3 24	$8M	$46.3K	$9M
Q4 24	$6M	$55.8K	$7M
Q1 25	$8M	$39.9K	$8M
Q2 25	$6M	$73.9K	$7M
Q3 25	$5M	$33.5K	$5M
Q4 25	$2M	$165.4K	$2M
Q1 26	$4M	$143.3K	$4M
Q2 26	$5M	$141.3K	$5M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 22	6M	+0.7%	+16.6%
Q4 22	6M	-1.1%	+15.3%
Q1 23	6M	+1.1%	+3.9%
Q2 23	6M	0.0%	+0.7%
Q3 23	6M	+8.2%	+8.2%
Q4 23	7M	+2.7%	+12.4%
Q1 24	9M	+36.9%	+52.1%
Q2 24	11M	+18.9%	+80.9%
Q3 24	14M	+28.7%	+115.1%
Q4 24	13M	-5.3%	+98.4%
Q1 25	17M	+27.1%	+84.2%
Q2 25	18M	+5.1%	+62.7%
Q3 25	18M	+4.5%	+32.1%
Q4 25	20M	+6.9%	+49.1%
Q1 26	21M	+9.3%	+28.2%
Q2 26	24M	+14.4%	+39.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 22	$16.6K	6
Q4 22	$15.9K	7
Q1 23	$14.0K	7
Q2 23	$2.9K	7
Q3 23	$11.1K	7
Q4 23	$6.1K	5
Q1 24	$30.3K	5
Q2 24	$29.0K	5
Q3 24	$16.8K	5
Q4 24	$9.3K	9
Q1 25	$20.4K	9
Q2 25	$19.3K	9
Q3 25	$19.3K	9
Q4 25	$19.3K	9
Q1 26	$0	9
Q2 26	$2.2K	9

Revenue / Employee